Yesway, Inc.: the filing proof gates that matter now
Yesway, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
608Results20Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAditxt: The Biotech Roll-Up Fighting Nasdaq Before It Fights Disease
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenActuate Therapeutics: the survival signal with a July cash wall
Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAclarion: the $19M cash pile chasing a tiny Nociscan revenue line
Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAgilent Technologies (A): the lab-workflow compounder still waiting for the cycle to turn
Agilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
OpenZevra Therapeutics, Inc.: the filing proof gates that matter now
Zevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenYum China: the KFC China engine still has to beat traffic and capex math
Yum China reported FY2025 revenue of $11.8 billion and Q1 2026 revenue of $3.3 billion. The thesis depends on same-store demand, restaurant expansion, delivery economics, China consumer conditions, margin control and capex discipline.
OpenYatra Online, Inc.: the filing proof gates that matter now
Yatra Online, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZscaler: the zero-trust growth story still has to turn into clean GAAP profit
Zscaler reported FY2025 revenue of $2.7 billion and Q2 FY2026 revenue of $815.8 million. The thesis depends on zero-trust demand, large-customer expansion, billings quality, operating leverage, stock compensation and cash conversion.
OpenZentalis Pharmaceuticals, Inc.: the filing proof gates that matter now
Zentalis Pharmaceuticals, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZoom: the cash-rich meeting platform has to prove AI can restart durable growth
Zoom reported FY2026 revenue of $4.9 billion and Q3 FY2026 revenue of $1.2 billion. The thesis depends on enterprise retention, Zoom Phone, contact center, AI features, margin durability and cash conversion.
OpenKinder Morgan: the pipeline cash machine still lives under a leverage ceiling
Kinder Morgan reported 2025 revenue of $15.20 billion, operating income of $4.72 billion and operating cash flow of $5.92 billion. The Coverage Bootstrap question is whether natural-gas infrastructure cash flow can keep funding dividends and projects without l
OpenClear Secure: the identity network has to prove airport scale travels
Clear Secure reported FY2025 revenue of $900.8 million and Q1 2026 revenue of $253.0 million, with the official record tying the thesis to airport-member growth, identity platform expansion, deferred revenue, privacy trust, margin quality and cash conversion.
OpenZipRecruiter, Inc.: the filing proof gates that matter now
ZipRecruiter, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenJoby Aviation: certification progress still has to beat the cash-burn clock
Joby reported 2025 revenue of $53.4 million, a $719.6 million operating loss and latest cash of $874.5 million. The Coverage Bootstrap question is whether certification, manufacturing and air-taxi commercialization can arrive before losses and capital needs di
Open111, Inc.: the filing proof gates that matter now
111, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZillow Group: housing traffic has to become profitable transaction and software proof
ZG has an annual revenue baseline of $2.6B, latest revenue marker of $708M Q1 2026, annual net income of $23M and cash of $678M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.
Open